Insights and perspectives on how teams are adapting, partnering and growing across
pharma, biotech and medtech, driven by pharma industry trends
How manufacturing partnerships are becoming a strategic driver
Why execution, funding and scale are defining biotech success
How commercial strategy and positioning are reshaping advantage
Pharma industry trends, alongside developments in biotech and medtech, are shaping
how organisations approach development, partnerships and growth.
These perspectives explore how those shifts are beginning to reshape
decisions, timelines, and outcomes across the industry.
The next edition of Industry Intelligence will continue tracking the pharma industry trends shaping strategy across biotech and medtech..
Manufacturing now sits at the centre of pharma strategy. Patent cliffs are accelerating, timelines to reposition assets are shrinking, and the complexity of formulation, regulatory pathways, and specialised production continues to increase. What once operated effectively in house is now stretching beyond most organisations. CDMOs are evolving from additional capacity into critical partners in speed and execution, and the ability to work through them effectively is becoming a defining factor in how quickly therapies reach the market.
For biotech, pressure intensifies once a molecule shows promise. As biologics become more complex and advanced modalities move into the pipeline, formulation, manufacturability, and scale up are emerging as the key bottlenecks. Early stage de risking is becoming critical, yet many programmes still encounter late stage instability, regulatory uncertainty, and manufacturing gaps. The result is a growing dependence on external expertise, where the ability to partner effectively is starting to define which molecules successfully reach the market.
Medtech competition is shifting beyond the device itself. AI integration is accelerating while regulatory pathways remain uncertain, and supply chains are fragmenting across regions, forcing companies to rethink how and where products are built. At the same time, outcomes data and real world evidence are becoming central to commercial success, while manufacturing expertise is increasingly accessed through external partners. Advantage now sits with organisations that can coordinate these capabilities effectively, rather than those focused on advancing the product alone.
This issue explores three shifts shaping pharma, biotech and medtech strategy. From manufacturing pressure and formulation complexity to device integration and execution risk.
Each reflects where pressure is building, and how organisations are responding through changes in partnerships, formulation strategy and device design.
These shifts are already influencing how drug delivery challenges are being approached
across development and device strategy.
Pharma
Medtech
Pharma
Biotech
Biotech
Medtech
Biotech
Pharma
Biotech
Biotech
Biotech
The life sciences industry moves fast. Cut through the noise and digest the strategic intelligence leaders need
to stay ahead. Analysis that contextualises what’s happening, why it matters and what comes next.
